Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: an international multicenter randomized trial.
BCD-020 is a proposed rituximab biosimilar which has shown high similarity to rituximab in quality and non-clinical studies in vitro and in vivo. International multicenter clinical trial was conducted to compare efficacy and safety of BCD-020 and reference rituximab in adult (>18 years) patients with indolent lymphomas (follicular lymphoma grade 1-2, splenic marginal zone lymphoma, nodal marginal zone lymphoma). Pharmacokinetics, pharmacodynamics and immunogenicity were also studied. Patients with no previous biologic treatment for lymphoma were randomly assigned 1:1 to receive BCD-020 or comparator 375 mg/m2 for 4 weeks. Primary study outcome was day 50 overall response rate defined as complete or partial remission. Equivalence range was -20% to 20% for 95% CI for overall response rates difference. Secondary outcomes included adverse events, pharmacokinetics, pharmacodynamics and immunogenicity. 174 patients were enrolled, 89 in BCD-020 arm and 85 in comparator arm. The overall response rate was 44.71% in BCD-020 arm and 41.89% in comparator arm. Limits of 95% CI for difference of overall response rates between arms were [-12.62%; 18.24%] showing equivalent efficacy. 61 (68.54%) and 59 (69.41%) patients had at least 1 adverse event in BCD-020 arm or comparator arm, respectively. No unexpected adverse reactions were reported. Anti-drug antibodies with no neutralizing activity were detected in 2 patients in comparator arm on day 14 further declining below detection threshold. Rituximab concentrations had equivalent pattern after intravenous administration of both drugs. Both drugs caused depletion of B-cells without significant influence on other blood cell lineages. In this study we showed equivalent efficacy of BCD-020 and reference rituximab when used in patients with CD20-positive indolent lymphomas. We also confirmed pharmacokinetic equivalence of BCD-020 and reference rituximab. Safety profile, pharmacodynamics and immunogenicity of BCD-020 were also comparable to those of reference rituximab.